Jeffrey Johnson

Dr. Jeffrey Johnson

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Cell Reports
Verified
Journal Article
Open access
BHBingchen Han
Bingchen Han
YQYing Qu
Ying Qu
YJYanli Jin
Yanli Jin
YYYi Yu
Yi Yu
NDNan Deng
Nan Deng
XCXiaojiang Cui
Xiaojiang Cui
The mesoderm- and epithelial-mesenchymal transition-associated transcription factor FOXC1 is specifically overexpressed in basal-like breast cancer (BLBC), but its biochemical function is not understood. Here, we demonstrate that FOXC1 controls cancer stem cell (CSC) properties enriched in BLBC cells via activation of Smoothened (SMO)-independent Hedgehog (Hh) signaling. This non-canonical activation of Hh is specifically mediated by Gli2. Furthermore, we show that the N-terminal domain of FOXC1 (aa 1-68) binds directly to an internal region (aa 898-1168) of Gli2, enhancing the DNA-binding and transcription-activating capacity of Gli2. FOXC1 expression correlates with that of Gli2 and its targets in human breast cancers. Moreover, FOXC1 overexpression reduces sensitivity to anti-Hedgehog (Hh) inhibitors in BLBC cells and xenograft tumors. Together, these findings reveal FOXC1-mediated non-canonical Hh signaling that determines the BLBC stem-like phenotype and anti-Hh sensitivity, supporting inhibition of FOXC1 pathways as potential approaches for improving BLBC treatment.

4 April 2016 in Oncogene
Verified
Journal Article
Open access
PDF file
YYY Yu-Rice
Y Yu-Rice
YJY Jin
Y Jin
BHB Han
B Han
YQY Qu
Y Qu
JJJeffrey Johnson
Jeffrey Johnson
XCXiaojiang Cui
Xiaojiang Cui
Estrogen receptor-α (ERα) mediates the essential biological function of estrogen in breast development and tumorigenesis. Multiple mechanisms, including pioneer factors, coregulators and epigenetic modifications have been identified as regulators of ERα signaling in breast cancer. However, previous studies of ERα regulation have focused on luminal and HER2-positive subtypes rather than basal-like breast cancer (BLBC), in which ERα is underexpressed. In addition, mechanisms that account for the decrease or loss of ER expression in recurrent tumors after endocrine therapy remain elusive. Here, we demonstrate a novel FOXC1-driven mechanism that suppresses ERα expression in breast cancer. We find that FOXC1 competes with GATA-binding protein 3 (GATA3) for the same binding regions in the cis-regulatory elements upstream of the ERα gene and thereby downregulates ERα expression and consequently its transcriptional activity. The forkhead domain of FOXC1 is essential for the competition with GATA3 for DNA binding. Counteracting the action of GATA3 at the ERα promoter region, overexpression of FOXC1 hinders recruitment of RNA polymerase II and increases histone H3K9 trimethylation at ERα promoters. Importantly, ectopic FOXC1 expression in luminal breast cancer cells reduces sensitivity to estrogen and tamoxifen. Furthermore, in breast cancer patients with ER-positive primary tumors who received adjuvant tamoxifen treatment, FOXC1 expression is associated with decreased or undetectable ER expression in recurrent tumors. Our findings highlight a clinically relevant mechanism that contributes to the low or absent ERα expression in BLBC. This study suggests a new paradigm to study ERα regulation during breast cancer progression and indicates a role of FOXC1 in the modulation of cellular response to endocrine treatment.

17 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMichael Marotta
Michael Marotta
TOTaku Onodera
Taku Onodera
JJJeffrey Johnson
Jeffrey Johnson
GBG. Thomas Budd
G. Thomas Budd
TWTakaaki Watanabe
Takaaki Watanabe
HTHisashi Tanaka
Hisashi Tanaka
Oncogene amplification confers a growth advantage to tumor cells for clonal expansion. There are several, recurrently amplified oncogenes throughout the human genome. However, it remains unclear whether this recurrent amplification is solely a manifestation of increased fitness resulting from random amplification mechanisms, or if a genomic locus-specific amplification mechanism plays a role. Here we show that the ERBB2 oncogene at 17q12 is susceptible to palindromic gene amplification, a mechanism characterized by the inverted (palindromic) duplication of genomic segments, in HER2-positive breast tumors. We applied two genomic approaches to investigate amplification mechanisms: sequencing of DNA libraries enriched with tumor-derived palindromic DNA (Genome-wide Analysis of Palindrome Formation) and whole genome sequencing (WGS). We observed significant enrichment of palindromic DNA within amplified ERBB2 genomic segments. Palindromic DNA was particularly enriched at amplification peaks and at boundaries between amplified and normal copy-number regions. Thus, palindromic gene amplification shaped the amplified ERBB2 locus. The enrichment of palindromic DNA throughout the amplified segments leads us to propose that the ERBB2 locus is amplified through the mechanism that repeatedly generates palindromic DNA, such as Breakage-Fusion-Bridge cycles. The genomic architecture surrounding ERBB2 in the normal genome, such as segmental duplications, could promote the locus-specific mechanism.

23 August 2016 in Scientific Reports
Verified
Journal Article
Open access
YQYing Qu
Ying Qu
BZBo Zhou
Bo Zhou
WYWei Yang
Wei Yang
BHBingchen Han
Bingchen Han
YYYi Yu-Rice
Yi Yu-Rice
XCXiaojiang Cui
Xiaojiang Cui
Surface ectoderm (SE) cells give rise to structures including the epidermis and ectodermal associated appendages such as hair, eye and the mammary gland. In this study, we validate a protocol that utilizes BMP4 and the γ-secretase inhibitor DAPT to induce SE differentiation from human induced pluripotent stem cells (hiPSCs). hiPSC-differentiated SE cells expressed markers suggesting their commitment to the SE lineage. Computational analyses using integrated quantitative transcriptomic and proteomic profiling reveal that TGFβ superfamily signaling pathways are preferentially activated in SE cells compared with hiPSCs. SE differentiation can be enhanced by selectively blocking TGFβ-RI signaling. We also show that SE cells and neural ectoderm cells possess distinct gene expression patterns and signaling networks as indicated by functional Ingenuity Pathway Analysis. Our findings advance current understanding of early human SE cell development and pave the way for modeling of SE-derived tissue development, studying disease pathogenesis and development of regenerative medicine approaches.

20 September 2017 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NMNicholas Manguso
Nicholas Manguso
AGAlexandra Gangi
Alexandra Gangi
JJJeffrey Johnson
Jeffrey Johnson
AHAttiya Harit
Attiya Harit
NNNicholas Nissen
Nicholas Nissen
FAFarin Amersi
Farin Amersi

1 January 2025 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JRJai Min Ryu
Jai Min Ryu
CMChi Wei Mok
Chi Wei Mok
ATAntonio Toesca
Antonio Toesca
HLHung-Wen Lai
Hung-Wen Lai
WKWen-Ling Kuo
Wen-Ling Kuo
HPHyung Seok Park
Hyung Seok Park
Ryu JM, et al. J Breast Cancer. 2025 May;28:e18. https://doi.org/10.4048/jbc.2025.0030